Edition:
India

People: Denali Therapeutics Inc (DNLI.OQ)

DNLI.OQ on NASDAQ Stock Exchange Global Select Market

20.82USD
19 Jul 2019
Change (% chg)

$0.02 (+0.10%)
Prev Close
$20.80
Open
$20.73
Day's High
$21.50
Day's Low
$20.64
Volume
136,917
Avg. Vol
150,092
52-wk High
$28.84
52-wk Low
$12.36

Andersen, Dana 

Dr. Dana Andersen is Chief Technical and Manufacturing Officer of the Company. Dr. Andersen joins Denali from Genentech, where he served in various roles for nearly 23 years, working most recently as Vice President and Global Head of Technical Development Project & Portfolio Management. Prior to this role, he was Vice President of Pharmaceutical Development and held numerous leadership roles spanning biologics manufacturing process development at Genentech. Dr. Andersen is a fellow of the American Institute for Medical and Biological Engineering and received a B.S. from the University of Colorado at Boulder, and a M.S. and Ph.D. from Stanford University, all in chemical engineering with a focus on biological systems.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Marc Tessier-Lavignec

632,891

Ryan Watts

1,366,860

Alexander Schuth

1,076,940

Steve Krognes

1,166,560

Dana Andersen

--

Carole Ho

1,368,000
As Of  31 Dec 2017